These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29955490)

  • 1. Topiramate in the treatment of Prader-Willi syndrome: A case report.
    East N; Maroney M
    Ment Health Clin; 2017 Jan; 7(1):7-9. PubMed ID: 29955490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.
    Bonnot O; Cohen D; Thuilleaux D; Consoli A; Cabal S; Tauber M
    Eur J Pediatr; 2016 Jan; 175(1):9-18. PubMed ID: 26584571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.
    Gunay-Aygun M; Schwartz S; Heeger S; O'Riordan MA; Cassidy SB
    Pediatrics; 2001 Nov; 108(5):E92. PubMed ID: 11694676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prader-Willi Syndrome: clinical concerns for the orthopaedic surgeon.
    Kroonen LT; Herman M; Pizzutillo PD; Macewen GD
    J Pediatr Orthop; 2006; 26(5):673-9. PubMed ID: 16932110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate effectiveness in Prader-Willi syndrome.
    Smathers SA; Wilson JG; Nigro MA
    Pediatr Neurol; 2003 Feb; 28(2):130-3. PubMed ID: 12699864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individuals with Smith-Magenis syndrome display profound neurodevelopmental behavioral deficiencies and exhibit food-related behaviors equivalent to Prader-Willi syndrome.
    Alaimo JT; Barton LV; Mullegama SV; Wills RD; Foster RH; Elsea SH
    Res Dev Disabil; 2015 Dec; 47():27-38. PubMed ID: 26323055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prader-Willi syndrome: an update on obesity and endocrine problems.
    Kim SJ; Cho SY; Jin DK
    Ann Pediatr Endocrinol Metab; 2021 Dec; 26(4):227-236. PubMed ID: 34991300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.
    Goldman VE; Naguib MN; Vidmar AP
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prader-Willi syndrome: Symptoms and topiramate response in light of genetics.
    Louveau C; Turtuluci MC; Consoli A; Poitou C; Coupaye M; Krebs MO; Chaumette B; Iftimovici A
    Front Neurosci; 2023; 17():1126970. PubMed ID: 36814790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome.
    Shapira NA; Lessig MC; Murphy TK; Driscoll DJ; Goodman WK
    Int J Neuropsychopharmacol; 2002 Jun; 5(2):141-5. PubMed ID: 12135538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of obesity in Prader-Willi syndrome.
    Khan MJ; Gerasimidis K; Edwards CA; Shaikh MG
    Pediatr Obes; 2018 Jan; 13(1):3-13. PubMed ID: 27863129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.
    Miller JL; Strong TV; Heinemann J
    Diseases; 2015 Jun; 3(2):78-85. PubMed ID: 28943610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A disease specific questionnaire for assessing behavior in individuals with Prader-Willi syndrome.
    Avrahamy H; Pollak Y; Shriki-Tal L; Genstil L; Hirsch HJ; Gross-Tsur V; Benarroch F
    Compr Psychiatry; 2015 Apr; 58():189-97. PubMed ID: 25677112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity management in Prader-Willi syndrome: current perspectives.
    Crinò A; Fintini D; Bocchini S; Grugni G
    Diabetes Metab Syndr Obes; 2018; 11():579-593. PubMed ID: 30323638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome.
    Bravo GL; Poje AB; Perissinotti I; Marcondes BF; Villamar MF; Manzardo AM; Luque L; LePage JF; Stafford D; Fregni F; Butler MG
    Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):266-75. PubMed ID: 26590516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of Prader-Willi syndrome: the endocrine approach.
    Heksch R; Kamboj M; Anglin K; Obrynba K
    Transl Pediatr; 2017 Oct; 6(4):274-285. PubMed ID: 29184809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive management of obesity in people with Prader-Willi syndrome.
    Nolan BJ; Proietto J; Sumithran P
    Endocrine; 2022 Jun; 77(1):57-62. PubMed ID: 35524875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored management of life-threatening complications related to severe obesity in a young adult with Prader-Willi syndrome.
    Kim MS; Kim J; Cho J; Cho SY; Jin DK
    Ann Pediatr Endocrinol Metab; 2022 Jun; 27(2):148-152. PubMed ID: 34670069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.